William Petty
Wake Forest University Health Sciences
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name William Petty as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 03:59 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT02949843 · Targeted Therapy in Treating Patients With Incurable Non-Small Cell Lung Cancer With Genetic MutationsWake Forest University Health Sciences · terminated · EGFR Activating Mutation, Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer · principal investigator
- Ph2NCT01557959 · Docetaxel, Cisplatin, Pegfilgrastim, and Erlotinib Hydrochloride in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung CancerWake Forest University Health Sciences · completed · Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer, Bronchoalveolar Cell Lung Cancer · principal investigator
- Ph2NCT01553539 · Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By SurgeryWake Forest University Health Sciences · completed · Bone Cancer, Chondrosarcoma, Clear Cell Sarcoma of the Kidney · principal investigator
- Ph2NCT01234922 · Benazepril Hydrochloride, Lisinopril, Ramipril, or Losartan Potassium in Treating Hypertension in Patients With Solid TumorsWake Forest University Health Sciences · terminated · Hypertension, Unspecified Adult Solid Tumor, Protocol Specific · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 03:59 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Cancer Prevention and Control Research ProgramP30CA012197 · NCI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI Ruben A. Mesa · fiscal years 2000 to 2026Named on NCT02949843
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 03:59 UTC. The ranking covers the 200 most relevant of 24 PubMed records, and a shared surname and initials can bring in a namesake. All 24 on PubMed
- Overcoming CYP1A1/1A2 mediated induction of metabolism by escalating erlotinib dose in current smokers.J Clin Oncol · 2009120 citationsRCR 3.1
- High-Dose Once-Daily Thoracic Radiotherapy in Limited-Stage Small-Cell Lung Cancer: CALGB 30610 (Alliance)/RTOG 0538.J Clin Oncol · 202399 citationsRCR 7.3
- Phase I and pharmacokinetic study of angiotensin-(1-7), an endogenous antiangiogenic hormone.Clin Cancer Res · 200983 citationsRCR 2.3
- A proof-of-principle clinical trial of bexarotene in patients with non-small cell lung cancer.Clin Cancer Res · 200772 citationsRCR 1.6
- Incorporating bevacizumab and erlotinib in the combined-modality treatment of stage III non-small-cell lung cancer: results of a phase I/II trial.J Clin Oncol · 201265 citationsRCR 1.6
- Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab Plus Talazoparib in Patients With SLFN11 Positive Extensive-Stage SCLC: S1929.J Thorac Oncol · 202565 citationsRCR 12.7
- Long-Term Outcomes of a Phase 2 Trial of Chemotherapy With Consolidative Radiation Therapy for Oligometastatic Non-Small Cell Lung Cancer.Int J Radiat Oncol Biol Phys · 201859 citationsRCR 2.1
- A Phase II Clinical Trial of CPI-613 in Patients with Relapsed or Refractory Small Cell Lung Carcinoma.PLoS One · 201657 citationsRCR 1.7
- Bexarotene and erlotinib for aerodigestive tract cancer.J Clin Oncol · 200548 citationsRCR 0.9
- Berzosertib Plus Topotecan vs Topotecan Alone in Patients With Relapsed Small Cell Lung Cancer: A Randomized Clinical Trial.JAMA Oncol · 202348 citationsRCR 3.6